Member News - TAGLaw

Paul Tauber, Chair of Coblentz, Patch, Duffy & Bass LLP's corporate practice, completed a round of Series E financing for client, Chronix Biomedical, a privately held company. The company is applying proprietary techniques that utilize serum DNA to develop routine blood tests for the early detection and management of cancer.

According to Chronix CEO Howard Umovitz, quoted in a Reuters Health and Science press release, "If the breast cell is injured, it will overexpress the genes that make it a breast cell. In theory, if a patient has excess DNA from breast cells that are dying, there is something going on that is killing breast cells." Chronix Biomedical focuses on blood tests for breast and prostate cancer. In-house validation tests have shown that these new genetic tests can outperform the existing gold standards. Chronix is headquartered in San Jose, California, and has a research facility in Germany.